Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue

Pharmaceutical Development and Technology

Volumn 11, Issue 4, 2006, Pages 513-519

  Na, Dong Hee ^a   Youn, Yu Seok ^b   Lee, In Bok ^b   Park, Eun Ji ^b   Park, Chong Jeon ^b   Lee, Kang Choon ^b  

^a Kyungsung University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Biological activity; PEGylation; Protein stability; Recombinant human epidermal growth factor; Wound healing

Indexed keywords

BUTYRALDEHYDE; MACROGOL; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR MACROGOL; TOPICAL AGENT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RAT; SKIN INJURY; TOPICAL TREATMENT; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG STABILITY; EPIDERMAL GROWTH FACTOR; HUMANS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; RATS; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 33845201165     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450600941053     Document Type: Article

References (34)

1. Carpenter, G.; Cohen, S. Epidermal growth factor. J. Biol. Chem. 1990, 4265, 7709-7712.
2. Han, K.; Lee, K.D.; Gao, Z.G.; Park, J.S. Preparation and evaluation of poly(L-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J. Control. Release 2001, 75, 259-269.
3. Mansbridge, J.N.; Liu, K.; Pinney, R.E.; Patch, R.; Ratcliffe, A.; Naughton, G.K. Growth factors secreted by fibroblasts: Role in healing diabetic foot ulcers. Diabetes Obes. Metab. 1999, 1, 265-279.
4. Hebda, P.A. Stimulatory effects of transforming growth factorbeta and epidermal growth factor on epidermal cell out-growth for porcine skin explant cultures. J. Invest. Dermatol. 1988, 91, 440-445.
5. Brown, G.L.; Nanney, L.B.; Griffen, J.; Cramer, A.B.; Yancey, J.M.; Curtsinger, L.J.; Holtzin, L.; Schultz, G.S.; Jurkiewicz, M.J.; Lynch, J.B. Enhancement of wound healing by topical treatment with epidermal growth factor. N. Engl. J. Med. 1989, 321, 76-79.
6. Falanga, V.; Eaglstein, W.H.; Bucalo, B.; Katz, M.H.; Harris, B.; Carson, P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J. Dermatol. Surg. Oncol. 1992, 18, 604-606.
7. Limat, A.; French, L.E. Therapy with growth factors. Curr. Probl. Dermatol, 1999, 27, 49-56.
8. Tarnuzzer, R.W.; Macauley, S.P.; Mast, B.A.; Gibson, J.S.; Stacey, M.C.; Trengrove, N.; Moldawer, L.L.; Burslem, F.; Schultz, G.S. Epidermal growth factor in wound healing: A model for the molecular pathogenesis of chronic wounds. In Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications; Ziegler, T.R.; Pierce, G.F.; Herndon, D.N. (Eds.); Springer-Verlag: New York, 1997, 206-228.
9. Greaves, M.W. Lack of effect of topically applied epidermal growth factor (EGF) on epidermal growth in man in vivo. Clin. Exp. Dermatol. 1980, 5, 101-103.
10. Okumura, K.; Kiyohara, Y.; Komada, F.; Iwakawa, S.; Hirai, M.; Fuwa, T. Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Pharm. Res. 1990, 7, 1289-1293.
11. Araki, F.; Nakamura, H.; Nojima, N.; Tsukumo, K.; Sakamoto, S. Stability of recombinant human epidermal growth factor in various solutions. Chem. Pharm. Bull. 1989, 37, 404-406.
12. Son, K.; Kwon, C. Stabilization of human epidermal growth factor (hEGF) in aqueous formulation. Pharm. Res. 1995, 12, 451-454.
13. Han, K.; Choi, M.S.; Chung, Y.B. Site-specific degradation and transport of recombinant human epidermal growth factor (rhEGF) in the rat gastrointestinal mucosa. Int. J. Pharm. 1998, 168, 189-197.
14. Yang, C.H.; Huang, Y.B.; Wu, P.C.; Tsai, Y.H. 2000. The evaluation of stability of recombinant human epidermal growth factor in burn-injured pigs. Process Biochem. 2000, 40, 1661-1665.
15. Lee, K.C.; Moon, S.C.; Park, M.O.; Lee, J.T.; Na, D.H.; Yoo, S.D.; Lee, H.S.; DeLuca, P.P. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 1999, 16, 813-818.
16. Esposito, P.; Barbero, L.; Caccia, P.; Caliceti, P.; D'Antonio, M.; Piquet, G.; Veronese, F.M. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Deliv. Rev. 2003, 55, 1279-1291.
17. Na, D.H.; Youn, Y.S.; Park, E.J.; Lee, J.M.; Cho, O.R.; Lee, K.R.; Lee, S.D.; Yoo, S.D.; DeLuca, P.P.; Lee, K.C. Stability of PEGylated salmon calcitonin in nasal mucosa. J. Pharm. Sci. 2004, 93, 256-261.
18. Na, D.H.; DeLuca, P.P. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co- glycolide). Pharm. Res. 2005, 22, 736-742.
19. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.
20. Kim, T.H.; Lee, H.; Park, T.G. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 2002, 23, 2311-2317.
21. Lee, H.; Kim, T.H.; Park, T.G. A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. J. Control. Release 2002, 83, 109-119.
22. Lee, H.; Park, T.G. Preparation and characterization of mono-PEGylated epidermal growth factor. Evaluation of in vitro biologic activity. Pharm. Res. 2002, 19, 845-851.
23. Lee, H.; Jang, I.H.; Ryu, S.H.; Park, T.G. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 2003, 20, 818-825.
24. Kinstler, O.B.; Brems, D.N.; Lauren, S.L.; Paige, A.G.; Hamburger, J.B.; Treuheit, M.J. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 1996, 13, 996-1002.
25. Na, D.H.; Lee, K.C.; DeLuca, P.P. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm. Res. 2005, 22, 734-749.
26. Morpurgo, M.; Monfardini, C.; Hofland, L.J.; Sergi, M.; Orsolini, P.; Dumont, J.M.; Veronese, F.M. Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatin analogue: tailored chemistry for optimized bioconjugates. Bioconjug. Chem. 2002, 13, 1238-1243.
27. Na, D.H.; Park, M.O.; Choi, S.Y.; Kim, Y.S.; Lee, S.S.; Yoo, S.D.; Lee, H.S.; Lee, K.C. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Chromatogr. B. 2001, 754, 259-263.
28. Na, D.H.; Lee, K.C. Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 2004, 331, 322-328.
29. Na, D.H.; Youn, Y.S.; Lee, K.C. Optimization of the PEGylation process of a peptide by monitoring with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 2241-2244.
30. Na, D.H.; Youn, Y.S.; Lee, K.C. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring and optimization of site-specific PEGylation of ricin A-chain. Rapid Commun. Mass Spectrom. 2004, 18, 2185-2189.
31. Lee, H.S.; Lee, J.S.; Lee, H.; Jung, Y.S.; DeLuca, P.P.; Lee, K.C. Reversed-phase high-performance liquid chromatography of salmon calcitonin and its degradation products in biological samples using column switching and flow-through radioisotope detection. J. Chromatogr. B. 1995, 673, 136-141.
32. Gregory, H.; Thomas, C.E.; Young, J.A.; Willshire, I.R.; Garner, A. The contribution of the C-terminal undecapeptide sequence of urogastrone-epidermal growth factor to its biological action. Regul. Pept. 1988, 22, 217-226.
33. Shin, S.Y.; Shimizu, M.; Ohtaki, T.; Munekata, E. Synthesis and biological activity of N-terminal-truncated derivatives of human epidermal growth factor (h-EGF). Peptides 1995, 16, 205-210.
34. Morimoto, K.; Iwakura, Y.; Nakatani, E.; Miyazaki, M.; Tojima, H. Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats. J. Pharm. Pharmacol. 1992, 44, 216-218.